SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
03-Apr-24 5:23 PM View: | Treco Douglas A CEO Director | Inozyme Pharma, Inc. (INZY) | 02-Apr-24 | Option Sale | 7,523 | $6.94 | $52,209.60 | (27%) 28.19K to 20.66K | |
03-Apr-24 5:23 PM View: | Treco Douglas A CEO Director | Inozyme Pharma, Inc. (INZY) | 01-Apr-24 | Option Exercise | 25,000 | -- | -- | 784% 3.19K to 28.19K | |
03-Apr-24 5:23 PM View: | Winton Matthew COO | Inozyme Pharma, Inc. (INZY) | 28-Mar-24 | Grant | 3,188 | $3.33 | $10,616.00 | 100% 0 to 3.19K | |
03-Oct-23 4:05 PM View: | Subramanian Sanjay SVP, CFO | Inozyme Pharma, Inc. (INZY) | 29-Sep-23 | Grant | 2,319 | $3.57 | $8,278.83 | 8% 28.08K to 30.4K | |
03-Aug-23 8:01 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 01-Aug-23 | Private Purchase | 833,333 | $4.80 | $4,000,000.00 | 23% 3.66M to 4.49M | |
03-Aug-23 8:13 PM View: | Pivotal Bioventure Partners... Director | Inozyme Pharma, Inc. (INZY) | 01-Aug-23 | Private Purchase Duplicate | 833,333 | $4.80 | $4,000,000.00 | 23% 3.66M to 4.49M | |
15-May-23 5:06 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 12-May-23 | Market Purchase | 228,702 | $6.25 | $1,429,390.00 | 3% 6.87M to 7.09M | (< 1%) |
15-May-23 5:06 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 11-May-23 | Market Purchase | 219,230 | $6.48 | $1,420,610.00 | 3% 6.65M to 6.87M | (4%) |
04-Apr-23 8:40 AM View: | Bolte Axel Director | Inozyme Pharma, Inc. (INZY) | 31-Mar-23 | Grant | 4,806 | $2.21 | $10,621.30 | 2% 261.89K to 266.7K | |
04-Apr-23 8:37 AM View: | Subramanian Sanjay SVP, CFO | Inozyme Pharma, Inc. (INZY) | 31-Mar-23 | Grant | 979 | $2.21 | $2,163.59 | 4% 27.1K to 28.08K | |
30-Mar-23 5:46 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 29-Mar-23 | Private Purchase | 344,592 | $4.54 | $1,563,720.00 | 12% 2.87M to 3.21M | |
29-Mar-23 7:30 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 28-Mar-23 | Purchase | 156,766 | $4.16 | $652,335.00 | 3% 5.42M to 5.58M | |
29-Mar-23 7:30 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 27-Mar-23 | Private Purchase | 51,074 | $3.70 | $188,729.00 | < 1% 5.37M to 5.42M | |
19-Dec-22 8:30 AM View: | Bjarke Henric Bjorn SVP, COO | Inozyme Pharma, Inc. (INZY) | 15-Dec-22 | Private Purchase | 21,500 | $1.39 | $29,885.00 | 26% 83.94K to 105.44K | |
04-Oct-22 8:00 AM View: | Bolte Axel Chief Executive Officer Director | Inozyme Pharma, Inc. (INZY) | 30-Sep-22 | Grant | 3,315 | $2.28 | $7,558.20 | 1% 258.57K to 261.89K | |
04-Oct-22 8:00 AM View: | Bjarke Henric Bjorn SVP, COO | Inozyme Pharma, Inc. (INZY) | 30-Sep-22 | Grant | 3,315 | $2.28 | $7,558.20 | 4% 80.63K to 83.94K | |
20-Apr-22 4:05 PM View: | Hopfner Robert Lorne Director | Inozyme Pharma, Inc. (INZY) | 19-Apr-22 | Private Purchase | 1,070,000 | $3.69 | $3,948,300.00 | 67% 1.59M to 2.66M | |
21-Apr-22 6:04 PM View: | Longitude Capital Partners ... 10% Owner | Inozyme Pharma, Inc. (INZY) | 19-Apr-22 | Private Purchase | 1,355,000 | $3.69 | $4,999,950.00 | 48% 2.82M to 4.17M | |
20-Apr-22 4:05 PM View: | Bolte Axel Chief Executive Officer Director | Inozyme Pharma, Inc. (INZY) | 19-Apr-22 | Private Purchase | 67,750 | $3.69 | $249,998.00 | 36% 190.82K to 258.57K | |
20-Apr-22 4:05 PM View: | Bjarke Henric Bjorn SVP, COO | Inozyme Pharma, Inc. (INZY) | 19-Apr-22 | Private Purchase | 27,100 | $3.69 | $99,999.00 | 51% 53.53K to 80.63K | |
20-Apr-22 4:05 PM View: | Subramanian Sanjay SVP, CFO | Inozyme Pharma, Inc. (INZY) | 19-Apr-22 | Private Purchase | 27,100 | $3.69 | $99,999.00 | 100% 0 to 27.1K | |
20-Apr-22 6:22 PM View: | Pivotal Bioventure Partners... Director | Inozyme Pharma, Inc. (INZY) | 19-Apr-22 | Private Purchase Duplicate | 1,070,000 | $3.69 | $3,948,300.00 | 67% 1.59M to 2.66M | |
25-Jun-21 7:58 AM View: | Bolte Axel Chief Executive Officer Director | Inozyme Pharma, Inc. (INZY) | 24-Jun-21 | Option Sale | 66,788 | $0.00 | $6.68 | (26%) 257.61K to 190.82K | |
25-Jun-21 7:58 AM View: | Bolte Axel Chief Executive Officer Director | Inozyme Pharma, Inc. (INZY) | 24-Jun-21 | Option Exercise | 66,788 | $0.98 | $65,452.20 | 35% 190.82K to 257.61K | |
01-Feb-21 4:30 PM View: | Novo A/s 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jan-21 | Market Sale | 375,000 | $21.00 | $7,875,000.00 | (15%) 2.57M to 2.19M | (< 1%) |
28-Jul-20 6:15 PM View: | Jungles Steven J See Remarks | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 13,381 | -- | -- | 32% 42.04K to 55.42K | |
28-Jul-20 6:15 PM View: | Pivotal Bioventure Partners... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase Duplicate | 187,500 | $16.00 | $3,000,000.00 | 13% 1.4M to 1.59M | |
29-Jul-20 5:29 PM View: | Novo A/s 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 2,194,380 | -- | -- | 100% 0 to 2.19M | |
28-Jul-20 6:26 PM View: | New Enterprise Associates 1... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 2,187,690 | -- | -- | 100% 0 to 2.19M | |
28-Jul-20 6:26 PM View: | Baskett Forest 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase Duplicate | 250,000 | $16.00 | $4,000,000.00 | 11% 2.19M to 2.44M | |
28-Jul-20 6:28 PM View: | Makhzoumi Mohamad 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 2,187,690 | -- | -- | 100% 0 to 2.19M | |
28-Jul-20 6:29 PM View: | Makower Joshua 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase Duplicate | 250,000 | $16.00 | $4,000,000.00 | 11% 2.19M to 2.44M | |
28-Jul-20 6:30 PM View: | Sonsini Peter W. 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 2,187,690 | -- | -- | 100% 0 to 2.19M | |
28-Jul-20 6:13 PM View: | Schlessinger Joseph 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 13,381 | -- | -- | 5% 273.1K to 286.48K | |
28-Jul-20 6:11 PM View: | Hopfner Robert Lorne Director 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase | 187,500 | $16.00 | $3,000,000.00 | 13% 1.4M to 1.59M | |
28-Jul-20 8:53 PM View: | Rock Springs Capital Manage... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 467,884 | -- | -- | 45% 1.04M to 1.51M | |
28-Jul-20 6:11 PM View: | Alexion Pharmaceuticals Inc 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 1,109,910 | -- | -- | 100% 0 to 1.11M | |
28-Jul-20 6:33 PM View: | Ra Capital Management, LLC 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 1,403,650 | -- | -- | 100% 0 to 1.4M | |
29-Jul-20 5:29 PM View: | Novo A/s 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase | 375,000 | $16.00 | $6,000,000.00 | 17% 2.19M to 2.57M | |
28-Jul-20 6:26 PM View: | New Enterprise Associates 1... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase | 250,000 | $16.00 | $4,000,000.00 | 11% 2.19M to 2.44M | |
28-Jul-20 6:27 PM View: | Florence Anthony A. Jr. 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 2,187,690 | -- | -- | 100% 0 to 2.19M | |
28-Jul-20 6:28 PM View: | Makhzoumi Mohamad 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase Duplicate | 250,000 | $16.00 | $4,000,000.00 | 11% 2.19M to 2.44M | |
28-Jul-20 6:29 PM View: | Sandell Scott D 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 2,187,690 | -- | -- | 100% 0 to 2.19M | |
29-Jul-20 6:06 AM View: | Sanofi-Aventis 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 438,875 | -- | -- | 100% 0 to 438.88K | |
28-Jul-20 6:30 PM View: | Sonsini Peter W. 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase Duplicate | 250,000 | $16.00 | $4,000,000.00 | 11% 2.19M to 2.44M | |
28-Jul-20 6:20 PM View: | Longitude Capital Partners ... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 2,194,380 | -- | -- | 100% 0 to 2.19M | |
28-Jul-20 6:08 PM View: | Sofinnova Venture Partners ... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion | 1,590,810 | -- | -- | 100% 0 to 1.59M | |
28-Jul-20 8:53 PM View: | Rock Springs Capital Manage... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase Duplicate | 600,000 | $16.00 | $9,600,000.00 | 40% 1.51M to 2.11M | |
28-Jul-20 6:15 PM View: | Pivotal Bioventure Partners... 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Conversion Duplicate | 1,403,650 | -- | -- | 100% 0 to 1.4M | |
28-Jul-20 6:33 PM View: | Ra Capital Management, LLC 10% Owner | Inozyme Pharma, Inc. (INZY) | 28-Jul-20 | Purchase | 600,000 | $16.00 | $9,600,000.00 | 43% 1.4M to 2.0M |